BookPDF Available

Fundamentação científica do princípio da similitude na farmacologia moderna (2ª edição - revisada e atualizada) [eBook PDF - Coleção 'Novos Medicamentos Homeopáticos' - Volume I ]

Authors:
  • School of Medicine University of Sao Paulo
Book

Fundamentação científica do princípio da similitude na farmacologia moderna (2ª edição - revisada e atualizada) [eBook PDF - Coleção 'Novos Medicamentos Homeopáticos' - Volume I ]

Abstract

Realizando a ponte entre a farmacologia homeopática (princípio da similitude) e a farmacologia moderna, encontramos uma infinidade de relatos, tanto em compêndios farmacológicos como em experimentos e ensaios clínicos publicados em periódicos científicos, que descrevem uma reação do organismo oposta e secundária a uma ação primária da droga, confirmando a teoria hahnemanniana. Essa ação secundária do organismo, no sentido de manter a homeostase orgânica, é denominada de efeito rebote ou reação paradoxal segundo a racionalidade científica moderna, sendo usada pela homeopatia como resposta terapêutica.
A preview of the PDF is not available
ResearchGate has not been able to resolve any citations for this publication.
Article
The authoritative reference to bone diseases and disorders of mineral metabolism, revised and updated Now in its ninth edition, The Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism offers an updated and comprehensive guide to bone and mineral health. Since it was first published 30 years ago, the Primer has become the leading reference on the topic. With contributions from noted experts, the text explores basic biological factors of healthy development and disease states and makes the information accessible for clinical interventions. The ninth edition provides concise coverage of the widest possible spectrum of metabolic bone diseases and disorders of mineral metabolism. The new edition of this invaluable reference expands coverage and includes the most recent developments in the field that help to strengthen its usefulness and ensure that the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism maintains its place as the pre-eminent reference on bone and mineral health. This vital resource: • Provides the most accurate, up-to-date evidence-based information on basic and clinical bone science • Includes more than 10 new chapters and contributions from 300 authors from wide-ranging international research centers • Captures the very cutting edge of research covering mineral homeostasis, osteoporosis and other metabolic bone diseases, skeletal measurement technologies, and genetics • Presents a new companion website with useful supplementary materials at www.asbmrprimer.com Written for advanced students, clinicians, and researchers working in the field of bone health and disease, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism is the definitive, one-stop reference for anyone working in the field of bone health and disease.
Article
Evaluated the theory that amphetamine anorexia and tolerance reflect the lowering of a set point for body-weight regulation. In Exp I, 18 male Long-Evans hooded rats given either 2 or 4 mg/kg dextro-amphetamine and access to milk ultimately achieved comparable levels of tolerance and maintained their weight at 94–96% of control levels. Thus, the level of maintained body weight was not dose-dependent. Increasing the doses resulted in renewed anorexia and weight loss and the appearance of behavioral stereotypies (Exp II). Whereas mean intake then recovered, body weight remained at 79–82% of control levels. However, milk intake for individual Ss was extremely variable. Such variability is inconsistent with the notion that body weight was actively regulated by caloric intake. Drug withdrawal had little further effect on intake, and it led to weight rebound in only 1 group. When subsequently retested with the original doses, both groups were again anorexic and showed more intense stereotypy. This finding suggested that drug withdrawal caused a general increase in sensitivity to amphetamine rather than a set-point-related change in feeding. Results do not support the set-point theory of amphetamine tolerance. (27 ref)
Article
BACKGROUND: Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment. METHODS: We randomly assigned 17,802 apparently healthy men and women with low-density lipoprotein (LDL) cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher to rosuvastatin, 20 mg daily, or placebo and followed them for the occurrence of the combined primary end point of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes. RESULTS: The trial was stopped after a median follow-up of 1.9 years (maximum, 5.0). Rosuvastatin reduced LDL cholesterol levels by 50% and high-sensitivity C-reactive protein levels by 37%. The rates of the primary end point were 0.77 and 1.36 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio for rosuvastatin, 0.56; 95% confidence interval [CI], 0.46 to 0.69; P<0.00001), with corresponding rates of 0.17 and 0.37 for myocardial infarction (hazard ratio, 0.46; 95% CI, 0.30 to 0.70; P=0.0002), 0.18 and 0.34 for stroke (hazard ratio, 0.52; 95% CI, 0.34 to 0.79; P=0.002), 0.41 and 0.77 for revascularization or unstable angina (hazard ratio, 0.53; 95% CI, 0.40 to 0.70; P<0.00001), 0.45 and 0.85 for the combined end point of myocardial infarction, stroke, or death from cardiovascular causes (hazard ratio, 0.53; 95% CI, 0.40 to 0.69; P<0.00001), and 1.00 and 1.25 for death from any cause (hazard ratio, 0.80; 95% CI, 0.67 to 0.97; P=0.02). Consistent effects were observed in all subgroups evaluated. The rosuvastatin group did not have a significant increase in myopathy or cancer but did have a higher incidence of physician-reported diabetes. CONCLUSIONS: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. (ClinicalTrials.gov number, NCT00239681.) 2008 Massachusetts Medical Society